Get the Stockscreener App
8.92
0.45%
-0.04
After Hours:
8.95
0.03
+0.34%
Evolus Inc stock is traded at $8.92, with a volume of 1.24M.
It is down -0.45% in the last 24 hours and down -3.15% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$8.96
Open:
$9.01
24h Volume:
1.24M
Relative Volume:
1.22
Market Cap:
$575.12M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-8.2593
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-7.56%
1M Performance:
-3.15%
6M Performance:
-36.15%
1Y Performance:
-28.18%
1-Day Range:
$8.76
$9.29
1-Week Range:
$8.76
$9.7205
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
8.92 | 577.70M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - FinancialContent
When is Evolus Inc. stock expected to show significant growthReal Time Watchlist With Low Risk - jammulinksnews.com
What makes Evolus Inc. stock price move sharplyEarnings Play Trade Plan With Alerts Shared - beatles.ru
How strong is Evolus Inc. company’s balance sheetSmart Portfolio Alerts That Work - jammulinksnews.com
Why Evolus Inc. stock attracts strong analyst attentionReversal Alert Based on RSI Indicator Confirmed - metal.it
Price Clustering Detected in Evolus Inc. StockLow Capital High Return Stock Plans Reviewed - metal.it
Live Chart Scan Detects Wedge Pattern in Evolus Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline - Yahoo Finance
What caused EOLS's Q3 2024 earnings to miss forecasts? - AInvest
Is EOLS's Q1 2025 earnings forecast optimistic? - AInvest
How reliable are EOLS's earnings forecasts historically? - AInvest
What institutional investors are buying Evolus Inc. stockValue Investing Picks For Beginners - jammulinksnews.com
Is it the right time to buy Evolus Inc. stockSuperior profit margins - jammulinksnews.com
How does Evolus Inc. compare to its industry peersRapid return acceleration - jammulinksnews.com
What is the dividend policy of Evolus Inc. stockUnmatched profit growth - jammulinksnews.com
Should I hold or sell Evolus Inc. stock in 2025Dynamic investment growth - jammulinksnews.com
How volatile is Evolus Inc. stock compared to the marketCapitalize on fast-growing investment opportunities - jammulinksnews.com
Is Evolus Inc. stock overvalued or undervaluedMarket-beating returns - jammulinksnews.com
What are analysts’ price targets for Evolus Inc. in the next 12 monthsGet professional guidance for market timing - jammulinksnews.com
Does Evolus Inc. stock perform well during market downturnsTremendous wealth creation - jammulinksnews.com
Is Evolus Inc. a good long term investmentUnstoppable profit momentum - PrintWeekIndia
Should I buy Evolus Inc. stock before earningsHigh-yield investments - jammulinksnews.com
What drives Evolus Inc. stock priceOutstanding growth strategies - PrintWeekIndia
What analysts say about Evolus Inc. stockLightning-fast growth - PrintWeekIndia
Evolus to Report Second Quarter Financial Results on August 5, 2025 - BioSpace
Evolus Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):